Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
NCT ID: NCT03407716
Last Updated: 2023-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
2 participants
INTERVENTIONAL
2019-03-01
2021-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
American Ginseng in Treating Patients With Cancer-Related Fatigue
NCT00182780
American Ginseng in Treating Patients With Fatigue Caused by Cancer
NCT00719563
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
NCT06395441
The Effects of Ginseng on Cancer-Related Fatigue
NCT01375114
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer
NCT05241405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the efficacy of ginseng on decreasing cancer-related fatigue (CRF) in post-treatment cancer survivors as measured by Multidimensional Fatigue Symptom Inventory MFSI-Short Form (SF) at 28 and 56 days compared to placebo-controlled group.
SECONDARY OBJECTIVES:
I. To assess the acceptability and feasibility of ginseng as therapy for CRF in posttreatment cancer survivors.
II. To evaluate toxicities and tolerability associated with 2,000 mg per day of North American ginseng extract AFX-2 (panax quinquefolius) when used for cancer-related fatigue.
III. To explore the impact of ginseng on secondary endpoints, various dimensions of fatigue as measured by the other subscales of the MFSI-SF, Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form, as well as the single measure of fatigue (captured on Fatigue Linear Analogue Scale).
IV. To determine clinically significant changes in fatigue scores per the various measures of fatigue using the global impression of change.
TERTIARY OBJECTIVES:
I. To explore the relationship between ginseng therapy, inflammation biomarker adiponectin, and post-treatment cancer survivors? fatigue.
OUTLINE: Patients are randomized into 1 of 2 groups.
GROUP I: Patients receive North American ginseng extract AFX-2 orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
After completion of study, patients are followed up at day 28 and 56.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (North American ginseng extract AFX-2)
Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
American Ginseng
Given PO
Laboratory Biomarker Analysis
Correlative studies
Questionnaire Administration
Correlative studies
GROUP II (placebo)
Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
Laboratory Biomarker Analysis
Correlative studies
Placebo
Given PO
Questionnaire Administration
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
American Ginseng
Given PO
Laboratory Biomarker Analysis
Correlative studies
Placebo
Given PO
Questionnaire Administration
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with chemotherapy and surgery
* Treatment has been completed (except hormone therapy) for \>= 90 days prior to registration
* No known evidence of disease
* Men or women with a history of CRF as defined by a score \>= 4 on the numeric analogue scale (0 ? 10) (Eligibility Question Fatigue Scale)
* Presence of CRF \>= 30 days prior to registration
* Hemoglobin \>= 11.0 g/dL obtained =\< 180 days prior to registration
* Serum glutamic-oxaloacetic transaminase (SGOT) =\< 1.5 x upper limit of normal (ULN) obtained =\< 180 days prior to registration
* Creatinine =\< 1.2 X ULN obtained =\< 180 days prior to registration
* Ability to complete questionnaire(s) in English by themselves or with assistance
* Provide written informed consent
* Willing to return to enrolling institution for follow-up of the study and optional crossover (if applicable)
* Willing to provide blood samples for correlative research purposes
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only
* Treatment cannot begin prior to re-registering to the crossover phase and will ideally begin =\< 7 days after registration for the crossover phase
Exclusion Criteria
* Use of ginseng capsules for fatigue, within the last 12 months
* Uncontrolled hypertension \>= 2 times as noted in medical history (diastolic blood pressure \> 100, systolic \> 160) =\< 90 days prior to registration
* Currently using any other pharmacologic agent to specifically treat fatigue including psychostimulants, antidepressants, etc., although antidepressants used to treat items other than fatigue (such as hot flashes) are allowed if the patient has been on a stable dose for \>= 30 days prior to registration and plans to continue for \>= 30 days after registration; erythropoietin agents to treat anemia are allowed
* Known brain metastasis or primary central nervous system (CNS) malignancy
* Chronic oral or intravenous systemic steroid use (defined as being used on a regular basis or who have a problem that has required ongoing use of steroids in the last 180 days for greater than 7 days)
* Diabetes (defined by being on oral hypoglycemics or insulin)
* Psychiatric disorder such as severe depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia; (defined per medical history)
* Major surgery =\< 28 days prior to registration
* Any of the following:
* Pregnant women
* Nursing women
* Women of childbearing potential who are unwilling to employ adequate contraception
* Treatable causes of fatigue have not been ruled out, at least by history and exam criteria, by the treating provider, such as uncontrolled pain, hypothyroidism, or insomnia; NOTE: if these are considered to be the primary cause for the patient?s fatigue then the patient is not eligible for this trial
* Patients with pain requiring opioid pain medication; NOTE: over the counter analgesics such as Tylenol or ibuprofen are allowed
* New use of Ambien and/or other benzodiazepines =\< 30 days prior to registration
* New use of sleep aids including melatonin =\< 30 days prior to registration
* Use of full anticoagulant doses of coumadin or heparin (exception: 1 mg/day of coumadin for preventing catheter clots is allowed)
* Use of monoamine oxidase inhibitors (MAOI) inhibitors
* Patients scoring greater than 4 on a 0 to 10 scale with regard to sleep troubles or pain
* Patients planning to start any type of cancer therapy during the 8 week, double blind, course of the study, once randomized on the study
* Patients with malnutrition, active infection, significant pulmonary disease and cardiovascular disease as determined by the physician as they could impact fatigue
* Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, high doses of caffeine, guarana, or anything called an ?adaptogen?)
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* History of myocardial infarction =\< 180 days prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noel Arring
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2017-02494
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC16C2
Identifier Type: OTHER
Identifier Source: secondary_id
MC16C2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.